Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension

Zeitschrift fur Gastroenterologie

Volumn 49, Issue 9, 2011, Pages 1258-1262

  Halank, M ^a   Knudsen, L ^b   Seyfarth, H J ^c   Ewert, R ^d   Wiedemann, B ^a   Kolditz, M ^a   Hoffken G ^a   Hoeper, M M ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

ambrisentan; cirrhosis; portopulmonary hypertension; pulmonary hypertension

Indexed keywords

ALANINE AMINOTRANSFERASE; AMBRISENTAN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ADULT; ARTICLE; BLOOD GAS ANALYSIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FEMALE; FOLLOW UP; GERMANY; HUMAN; LIVER FUNCTION TEST; MALE; PORTOPULMONARY HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE; EXERCISE TEST; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; PHENYLPROPIONATES; PYRIDAZINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80052398060     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0031-1273393     Document Type: Article

References (27)

1. Hoeper M M., Krowka M J., Strassburg C P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004 363 1461-1468 (Pubitemid 38586724)
2. Rodriguez-Roisin R, Krowka M J., Herve P et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004 24 861-880 (Pubitemid 39504442)
3. Halank M, Miehlke S, Kolditz M et al. Portopulmonary hypertension. Z Gastroenterol 2005 43 677-685 (Pubitemid 41080659)
4. Le Pavec J, Souza R, Herve P et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008 178 637-643
5. Hoeper M M., Seyfarth H J., Hoeffken G et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007 30 1096-1102 (Pubitemid 351194755)
6. Melgosa M T., Ricci G L., Garcia-Pagan J C. et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl 2010 16 348-356
7. Reichenberger F, Voswinckel R, Steveling E et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006 28 563-567 (Pubitemid 44794671)
8. Hemnes A R., Robbins I M. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 2009 15 15-19
9. Hoeper M M., Halank M, Marx C et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005 25 502-508 (Pubitemid 40331181)
10. Humbert M, Segal E S., Kiely D G. et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007 30 338-344 (Pubitemid 47194187)
11. Oudiz R J., Galie N, Olschewski H et al. Long-term ambrisentan therapy for treatment of pulmonary arterial hypertension. JAm Coll Cardiol 2009 54 1971-1981
12. Krowka M J. Evolving dilemmas and management of portopulmonary hypertension. Seminars in Liver Disease 2006 26 265-272 (Pubitemid 44141934)
13. Galie N, Hoeper M M., Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009 30 2493-2537
14. ATS statement: guidelines for the six-minute walk test. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Am J Respir Crit Care Med 2002 166 111-117
15. Wensel R, Opitz C F., Anker S D. et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002 106 319-324 (Pubitemid 34778955)
16. Halank M, Ewert R, Seyfarth H J. et al. Portopulmonary hypertension. JGastroenterol 2006 41 837-847 (Pubitemid 44594224)
17. Cartin-Ceba R, Swanson K, Iyer V et al. Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension. Chest 2011 139 109-114
18. Rubin L J., Badesch D B., Barst R J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 346 896-903 (Pubitemid 34984638)
19. Halank M, Miehlke S, Hoeffken G et al. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004 77 1775-1776 (Pubitemid 38780551)
20. Molnar C, Alber H, Colleselli D et al. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis. Wien Klin Wochenschr 2004 116 627-630 (Pubitemid 39349835)
21. Grander W, Eller P, Fuschelberger R et al. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006 36 (Suppl 3) 67-70 (Pubitemid 44179785)
22. Hinterhuber L, Graziadei I W., Kähler C M. et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004 2 1039-1042 (Pubitemid 39539755)
23. Neuhofer W, Gülberg V, Gerbes A L. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest 2006 36 (Suppl 3) 54-61 (Pubitemid 44179783)
24. Stähler G, Hunnius P von. Succesful treatment of portopulmonary hypertension with bosentan: case report. Eur J Clin Invest 2006 36 (Suppl 3) 62-66 (Pubitemid 44179784)
25. Hino T, Hayashida A, Okahashi N et al. Portopulmonary hypertension associated with congenital absence of the portal vein treated with bosentan. Internal Medicine 2009 48 597-600
26. Giersbergen P L., Popescu G van, Bodin F et al. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. JClin Pharmacol 2003 43 15-22 (Pubitemid 36015438)
27. Hartman J C., Brouwer K, Mandagere A et al. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 2010 88 682-691